The use of high-dose cyclophosphamide without stem cell support has been proposed by physicians at John Hopkins University Hospital for many years as treatment for patients with newly diagnosed or refractory aplastic anemia. In this issue of Blood, Brodsky and colleagues report the long-term follow-up of their single-center clinical trial.